Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males

被引:41
|
作者
Stass, H [1 ]
Kubitza, D [1 ]
Möller, JG [1 ]
Delesen, H [1 ]
机构
[1] Bayer AG, Pharma Res Ctr, ICP, D-42096 Wuppertal, Germany
关键词
activated charcoal; moxifloxacin; pharmacokinetics;
D O I
10.1111/j.1365-2125.2005.02357.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To evaluate the extent to which enterohepatic recycling circulation contributes to moxifloxacin bioavailability in healthy, males by administration of activated charcoal and to evaluate the efficacy of activated charcoal administration in decreasing systemic concentrations of moxifloxacin in the event of overdose. Methods Nine healthy males, mean age 34 years (range 23-45 years) participated in a single centre, randomized, nonplacebo-controlled, three way crossover study. The pharmacokinetics of moxifloxacin in plasma and urine were determined for up to 96 h following a 400 mg single dose randomly administered on three separate occasions with a minimum washout phase of 1 week. Treatment A was 400 mg moxifloxacin IV as a 1 h infusion, treatment B was 400 mg moxifloxacin IV as a 1 h infusion with oral activated charcoal (5 g directly before the start of the infusion, 5 g immediately after the end of the infusion, and 10 g at 2, 4 and 8 h after the start of the infusion), treatment C was 400 mg oral moxifloxacin with activated charcoal (10 g 15 min before and at 2, 4 and 8 h after drug administration). The subjects underwent a series of clinical and laboratory tests. Results Single 400 mg doses of moxifloxacin (PO and/or IV) were safe and well tolerated. The bioavailability of moxifloxacin was significantly decreased when given with charcoal (AUC = 35.5 (IV reference) vs 5.40 (PO) vs 28.5 (IV) mg l(-1) h). Concurrently peak concentrations were lowered C-max = 3.38 (IV reference) vs 0.62(PO) vs 2.97 (IV) mg l(-1)) by approximately 85% (P < 0.05) following oral administration and by 20% after IV treatment (P < 0.05). Bioavailability amounted to 15.4% (95% confidence interval 9.6, 25.0%) for treatment B while it was 80.4% (95% confidence interval 76.3.6, 84.6%) for treatment C. Terminal half-lives were not affected. The kinetics of urinary excretion corroborated these findings. Conclusions The results of this study show that moxifloxacin undergoes pronounced enteric recycling after systemic uptake. In addition, these findings confirm that activated charcoal may be useful in treating moxifloxacin overdose by preventing its absorption.
引用
收藏
页码:536 / 541
页数:6
相关论文
共 50 条
  • [21] Pharmacokinetics of methyl parathion: A comparison following single intravenous, oral or dermal administration
    Kramer, RE
    Wellman, SE
    Rockhold, RW
    Baker, RC
    JOURNAL OF BIOMEDICAL SCIENCE, 2002, 9 (04) : 311 - 320
  • [22] Pharmacokinetics and Comparative Bioavailability Study of Two Clarithromycin Suspensions Following Administration of a Single Oral Dose to Healthy Volunteers
    Zakeri-Milani, Parvin
    Valizadeh, Hadi
    Ghanbarzadeh, Saeed
    Nemati, Mahboob
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2009, 59 (08): : 429 - 432
  • [23] Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers
    Stockis, A
    Deroubaix, X
    Lins, R
    Jeanbaptiste, B
    Calderon, P
    Rossignol, JF
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1996, 34 (08) : 349 - 351
  • [24] Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
    Hassan-Alin, M
    Andersson, T
    Bredberg, E
    Röhss, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (9-10) : 665 - 670
  • [25] The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects
    Sogaard, B
    Mengel, H
    Rao, N
    Larsen, F
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (12) : 1400 - 1406
  • [26] Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single-Dose Administration in Healthy Japanese and White Adults
    Glassman, Fiona
    Lawo, John-Philip
    Bica, Mihai Alexandru
    Roberts, Anthony
    Pawaskar, Dipti
    Akama, Hideto
    Jain, Meena
    Goodson, Summer
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, : 466 - 477
  • [27] Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males
    Persiani, S
    D'Amato, M
    Makovec, F
    Tavares, IA
    Bishai, PM
    Rovati, LC
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2002, 40 (05) : 198 - 206
  • [28] Comparative pharmacokinetics of a single dose of ampicillin following intravenous, intramuscular and subcutaneous administration to llamas
    Kreil, V.
    Prados, A. P.
    Ambros, L.
    Monfrinotti, A.
    Quaine, P.
    Hallu, R.
    Rebuelto, M.
    ARCHIVOS DE MEDICINA VETERINARIA, 2014, 46 (02) : 271 - 276
  • [29] Pharmacokinetics and bioavailability of tildipirosin in rabbits following single-dose intravenous and intramuscular administration
    Xiong, Jincheng
    Xu, Yuliang
    He, Shuang
    Zhang, Yanfang
    Wang, Zile
    Wang, Sihan
    Jiang, Haiyang
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2020, 43 (05) : 448 - 453
  • [30] Pharmacokinetics and pharmacodynamics of d-chlorpheniramine following intravenous and oral administration in healthy Thoroughbred horses
    Kuroda, Taisuke
    Nagata, Shun-ichi
    Takizawa, Yoshimasa
    Tamura, Norihisa
    Kusano, Kanichi
    Mizobe, Fumiaki
    Harju, Kazuhisa
    VETERINARY JOURNAL, 2013, 197 (02) : 433 - 437